These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38264403)

  • 1. Review and expert opinion on MAFLD, oxidative stress and multifunctional management.
    Angelico F; Alcantara-Payawal D; Rani RA; Mustafa N; Thongtang N; Chaiteerakij R; Bunchorntavakul C; Sukonthasarn A
    Drugs Context; 2024; 13():. PubMed ID: 38264403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silymarin in the management of liver enzyme activity in steatohepatitis: a case report.
    Torre A
    Drugs Context; 2023; 12():. PubMed ID: 37077767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.
    Kaya E; Yilmaz Y
    J Clin Transl Hepatol; 2022 Apr; 10(2):329-338. PubMed ID: 35528971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.
    Angelico F
    Drugs Context; 2024; 13():. PubMed ID: 38332944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
    Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
    Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of awareness and ethnic polarity is a major cause of metabolic associated fatty liver disease in high-risk diabetes population in South London.
    Ajaz S; Chamley M; Lok J; Soliman R; Khan R; Ahir K; Curtis M; Guerra-Veloz MF; Agarwal K
    Ther Adv Chronic Dis; 2024; 15():20406223241264539. PubMed ID: 39091507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
    Zhou XD; Targher G; Byrne CD; Somers V; Kim SU; Chahal CAA; Wong VW; Cai J; Shapiro MD; Eslam M; Steg PG; Sung KC; Misra A; Li JJ; Brotons C; Huang Y; Papatheodoridis GV; Sun A; Yilmaz Y; Chan WK; Huang H; Méndez-Sánchez N; Alqahtani SA; Cortez-Pinto H; Lip GYH; de Knegt RJ; Ocama P; Romero-Gomez M; Fudim M; Sebastiani G; Son JW; Ryan JD; Ikonomidis I; Treeprasertsuk S; Pastori D; Lupsor-Platon M; Tilg H; Ghazinyan H; Boursier J; Hamaguchi M; Nguyen MH; Fan JG; Goh GB; Al Mahtab M; Hamid S; Perera N; George J; Zheng MH
    Hepatol Int; 2023 Aug; 17(4):773-791. PubMed ID: 37204656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report.
    Chantarojanasiri T
    Drugs Context; 2023; 12():. PubMed ID: 37077770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
    Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
    Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37342459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review.
    Leca BM; Lagojda L; Kite C; Karteris E; Kassi E; Randeva HS; Kyrou I
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):335-348. PubMed ID: 38860684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic developments in metabolic dysfunction-associated fatty liver disease.
    Shi Y; Fan J
    Chin Med J (Engl); 2022 May; 135(9):1009-1018. PubMed ID: 35234696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease.
    Badmus OO; Hinds TD; Stec DE
    Curr Hypertens Rep; 2023 Aug; 25(8):151-162. PubMed ID: 37191842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From MAFLD to hepatocellular carcinoma and everything in between.
    Bae SDW; George J; Qiao L
    Chin Med J (Engl); 2022 Feb; 135(5):547-556. PubMed ID: 35191421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.